The large EPS miss on a minimal base is a mechanical artifact and not a reflection of business deterioration — the key driver is commercial execution on Ryoncil. Watch for continued revenue growth updates from major U.S. pediatric centers. The cross-filing activist context amplifies pressure, making any positive revenue updates more impactful.
Price Chart
Executive Summary
Mesoblast reported Q1 FY2026 EPS of -$0.07, missing consensus of -$0.03 by 133%. However, the company announced full-year Ryoncil net revenue of $115M, exceeding initial projections, with continued growth expected. The EPS miss is on a tiny base and the Ryoncil revenue narrative is the dominant driver, making the overall tone mixed.
Key Financial Metrics
Key Facts
- FY2026 Q1 EPS: -$0.07, -133% miss vs consensus -$0.03.
- Ryoncil net revenue of US$36M for Q1 FY2026 and US$115M for full year ended June 30, 2026.
- CEO stated revenue exceeded initial projections and anticipates continued growth.
Financial Impact
Revenue of $115M for FY2026, exceeding projections; EPS of -$0.07 vs -$0.03 estimate.
Risk Factors
- Ryoncil revenue growth may not sustain the initial launch momentum.
- Reliance on a single product for near-term revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3325284 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | 20-F | $18.18 $15.48 | ▼ −14.85% | ▼ −14.34% | $14.07 (−22.58%) |
Aug 27, 2026 5w ago | Press Release | $18.18 $15.48 | ▼ −14.85% | ▼ −14.34% | $14.07 (−22.58%) |
Aug 24, 2026 5w ago | 6-K | $16.64 $15.92 | ▼ −4.33% | ▼ −5.64% | $14.07 (−15.41%) |
Aug 17, 2026 6w ago | Press Release | $17.02 $14.74 | ▼ −13.40% | ▼ −11.42% | $14.07 (−17.30%) |
Jul 30, 2026 9w ago | 6-K | $14.55 $18.18 | ▲ +24.95% | ▲ +20.98% | $14.07 (−3.26%) |
Jul 14, 2026 11w ago | 6-K | $16.74 $16.92 | ▲ +1.08% | ▼ −1.42% | $14.07 (−15.92%) |
Jul 14, 2026 11w ago | Press Release | $16.74 $16.92 | ▲ +1.08% | ▼ −1.42% | $14.07 (−15.92%) |
Jul 10, 2026 12w ago | 6-K | $15.44 $15.94 | ▲ +3.24% | ▲ +0.81% | $14.07 (−8.84%) |
Jul 10, 2026 12w ago | Press Release | $15.44 $15.94 | ▲ +3.24% | ▲ +0.81% | $14.07 (−8.84%) |
Jul 1, 2026 13w ago | 6-K | $14.09 $14.13 | ▲ +0.28% | ▲ +2.47% | $14.07 (−0.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access